TY - JOUR
T1 - Analysis of Clinical Samples of Pancreatic Cyst's Lesions with A Multi-Analyte Bioelectronic Simot Array Benchmarked Against Ultrasensitive Chemiluminescent Immunoassay
AU - Scandurra, Cecilia
AU - Björkström, Kim
AU - Caputo, Mariapia
AU - Sarcina, Lucia
AU - Genco, Enrico
AU - Modena, Francesco
AU - Viola, Fabrizio Antonio
AU - Brunetti, Celestino
AU - Kovács-Vajna, Zsolt M.
AU - Di Franco, Cinzia
AU - Haeberle, Lena
AU - Larizza, Piero
AU - Mancini, Maria Teresa
AU - Österbacka, Ronald
AU - Reeves, William
AU - Scamarcio, Gaetano
AU - Wheeler, May
AU - Caironi, Mario
AU - Cantatore, Eugenio
AU - Torricelli, Fabrizio
AU - Esposito, Irene
AU - Macchia, Eleonora
AU - Torsi, Luisa
N1 - Publisher Copyright:
© 2024 The Authors. Advanced Science published by Wiley-VCH GmbH.
PY - 2024/7/17
Y1 - 2024/7/17
N2 - Pancreatic cancer, ranking as the third factor in cancer-related deaths, necessitates enhanced diagnostic measures through early detection. In response, SiMoT-Single-molecule with a large Transistor multiplexing array, achieving a Technology Readiness Level of 5, is proposed for a timely identification of pancreatic cancer precursor cysts and is benchmarked against the commercially available chemiluminescent immunoassay SIMOA (Single molecule array) SP-X System. A cohort of 39 samples, comprising 33 cyst fluids and 6 blood plasma specimens, undergoes detailed examination with both technologies. The SiMoT array targets oncoproteins MUC1 and CD55, and oncogene KRAS, while the SIMOA SP-X planar technology exclusively focuses on MUC1 and CD55. Employing Principal Component Analysis (PCA) for multivariate data processing, the SiMoT array demonstrates effective discrimination of malignant/pre-invasive high-grade or potentially malignant low-grade pancreatic cysts from benign non-mucinous cysts. Conversely, PCA analysis applied to SIMOA assay reveals less effective differentiation ability among the three cyst classes. Notably, SiMoT unique capability of concurrently analyzing protein and genetic markers with the threshold of one single molecule in 0.1 mL positions it as a comprehensive and reliable diagnostic tool. The electronic response generated by the SiMoT array facilitates direct digital data communication, suggesting potential applications in the development of field-deployable liquid biopsy.
AB - Pancreatic cancer, ranking as the third factor in cancer-related deaths, necessitates enhanced diagnostic measures through early detection. In response, SiMoT-Single-molecule with a large Transistor multiplexing array, achieving a Technology Readiness Level of 5, is proposed for a timely identification of pancreatic cancer precursor cysts and is benchmarked against the commercially available chemiluminescent immunoassay SIMOA (Single molecule array) SP-X System. A cohort of 39 samples, comprising 33 cyst fluids and 6 blood plasma specimens, undergoes detailed examination with both technologies. The SiMoT array targets oncoproteins MUC1 and CD55, and oncogene KRAS, while the SIMOA SP-X planar technology exclusively focuses on MUC1 and CD55. Employing Principal Component Analysis (PCA) for multivariate data processing, the SiMoT array demonstrates effective discrimination of malignant/pre-invasive high-grade or potentially malignant low-grade pancreatic cysts from benign non-mucinous cysts. Conversely, PCA analysis applied to SIMOA assay reveals less effective differentiation ability among the three cyst classes. Notably, SiMoT unique capability of concurrently analyzing protein and genetic markers with the threshold of one single molecule in 0.1 mL positions it as a comprehensive and reliable diagnostic tool. The electronic response generated by the SiMoT array facilitates direct digital data communication, suggesting potential applications in the development of field-deployable liquid biopsy.
KW - bioelectronic transistors
KW - liquid biopsy
KW - multivariate data processing
KW - SIMOA-single-molecule-array-
KW - SiMoT-single-molecule-with-a-large-transistor
KW - single-molecule biosensors
KW - Immunoassay/methods
KW - Pancreatic Cyst/diagnosis
KW - Humans
KW - Proto-Oncogene Proteins p21(ras)/genetics
KW - Luminescent Measurements/methods
KW - Biomarkers, Tumor/genetics
KW - Pancreatic Neoplasms/diagnosis
KW - Sensitivity and Specificity
KW - Principal Component Analysis/methods
UR - http://www.scopus.com/inward/record.url?scp=85182849171&partnerID=8YFLogxK
U2 - 10.1002/advs.202308141
DO - 10.1002/advs.202308141
M3 - Article
C2 - 38234100
AN - SCOPUS:85182849171
SN - 2198-3844
VL - 11
SP - e2308141
JO - Advanced Science
JF - Advanced Science
IS - 27
M1 - 2308141
ER -